Acadia Pharmaceuticals 2022 Annual Report

Acadia Pharmaceuticals' 2022 annual report details the company's advancement in neuroscience with two FDA-approved therapies: NUPLAZID® for Parkinson's disease psychosis and DAYBUE™ for Rett syndrome. The report outlines the company's strategy for sustained growth, including DAYBUE's successful launch, NUPLAZID franchise expansion, and pipeline development for treatments of negative symptoms in schizophrenia and Alzheimer's disease psychosis.